Query String: DOXORUBICIN
CHEMBL386437 BDBM50155877 Doxorubicin-Formaldehyde Conjugate
Doxorubicin-Formaldehyde Conjugate BDBM50155875 CHEMBL264131
CHEMBL53463 Doxil Adriblastina BDBM22984 Adriamycin (8S,10S)-10-{[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione Doxorubicin
cid_443939 (7S,9S)-7-[(2R,4S,5S,6S)-4-azanyl-6-methyl-5-oxidanyl-oxan-2-yl]oxy-4-methoxy-6,9,11-tris(oxidanyl)-9-(2-oxidanylethanoyl)-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride MLS000028393 SMR000058570 (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-9-glycoloyl-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-quinone;hydrochloride (7S,9S)-7-[[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-2-oxanyl]oxy]-6,9,11-trihydroxy-9-(2-hydroxy-1-oxoethyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride DOXORUBICIN HYDROCHLORIDE BDBM32022
- Pallerla, S; Gauthier, T; Sable, R; Jois, SD Design of a doxorubicin-peptidomimetic conjugate that targets HER2-positive cancer cells. Eur J Med Chem 125: 914-924 (2017)
- Kusayanagi, T; Tsukuda, S; Shimura, S; Manita, D; Iwakiri, K; Kamisuki, S; Takakusagi, Y; Takeuchi, T; Kuramochi, K; Nakazaki, A; Sakaguchi, K; Kobayashi, S; Sugawara, F The antitumor agent doxorubicin binds to Fanconi anemia group F protein. Bioorg Med Chem 20: 6248-55 (2012)
- Burke, PJ; Koch, TH Design, synthesis, and biological evaluation of doxorubicin-formaldehyde conjugates targeted to breast cancer cells. J Med Chem 47: 1193-206 (2004)
- Arisawa, M; Kasaya, Y; Obata, T; Sasaki, T; Ito, M; Abe, H; Ito, Y; Yamano, A; Shuto, S Indomethacin Analogues that Enhance Doxorubicin Cytotoxicity in Multidrug Resistant Cells without Cox Inhibitory Activity. ACS Med Chem Lett 2: 353-357 (2011)
- Vucicevic, J; Srdic-Rajic, T; Pieroni, M; Laurila, JM; Perovic, V; Tassini, S; Azzali, E; Costantino, G; Glisic, S; Agbaba, D; Scheinin, M; Nikolic, K; Radi, M; Veljkovic, N A combined ligand- and structure-based approach for the identification of rilmenidine-derived compounds which synergize the antitumor effects of doxorubicin. Bioorg Med Chem 24: 3174-83 (2016)
- Kusunoki, N; Takara, K; Tanigawara, Y; Yamauchi, A; Ueda, K; Komada, F; Ku, Y; Kuroda, Y; Saitoh, Y; Okumura, K Inhibitory effects of a cyclosporin derivative, SDZ PSC 833, on transport of doxorubicin and vinblastine via human P-glycoprotein. Jpn J Cancer Res 89: 1220-8 (1999)
- Priebe, W; Krawczyk, M; Kuo, MT; Yamane, Y; Savaraj, N; Ishikawa, T Doxorubicin- and daunorubicin-glutathione conjugates, but not unconjugated drugs, competitively inhibit leukotriene C4 transport mediated by MRP/GS-X pump. Biochem Biophys Res Commun 247: 859-63 (1998)
- Cogan, PS; Koch, TH Rational design and synthesis of androgen receptor-targeted nonsteroidal anti-androgen ligands for the tumor-specific delivery of a doxorubicin-formaldehyde conjugate. J Med Chem 46: 5258-70 (2003)
- Burke, PJ; Kalet, BT; Koch, TH Antiestrogen binding site and estrogen receptor mediate uptake and distribution of 4-hydroxytamoxifen-targeted doxorubicin-formaldehyde conjugate in breast cancer cells. J Med Chem 47: 6509-18 (2004)
- Maimaitijiang, A; Wang, B; Yang, H; Tang, D; Liu, Y; Aisa, HA Discovery of a novel highly potent and low-toxic jatrophane derivative enhancing the P-glycoprotein-mediated doxorubicin sensitivity of MCF-7/ADR cells. Eur J Med Chem 244: (2022)
- Cogan, PS; Koch, TH Studies of targeting and intracellular trafficking of an anti-androgen doxorubicin-formaldehyde conjugate in PC-3 prostate cancer cells bearing androgen receptor-GFP chimera. J Med Chem 47: 5690-9 (2004)
- ChEMBL_1922230 (CHEMBL4425075) Inhibition of P-gp in doxorubicin-resistant human MCF7/ADR cells assessed as reversal of doxorubicin resistance by measuring doxorubicin IC50 incubated for 48 hrs by MTT assay (Rvb = doxorubicin alone = 64.8 +/- 2.1 uM)
- ChEMBL_2372722 Inhibition of P-gp-mediated multidrug resistance in doxorubicin-resistant human MCF7/ADR cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 incubated for 48 hrs by CCK-8 assay
- ChEMBL_579061 (CHEMBL1053122) Reversal of MRP1-mediated doxorubicin-resistance in human HeLa-T5 cells assessed as reduction of doxorubicin IC50 percent by half
- ChEMBL_579066 (CHEMBL1053127) Reversal of MRP1-mediated doxorubicin-resistance in human 2008/MRP1 cells assessed as reduction of doxorubicin IC50 percent by half
- ChEMBL_837643 (CHEMBL2076596) TP_TRANSPORTER: inhibition of Doxorubicin transepithelial transport (basal to apical) (Doxorubicin: 0.8 uM) in MDR1-expressing LLC-PK1 cells
- ChEMBL_2336436 Inhibition of ABCB1 in human HEK293 cells in the presence of doxorubicin
- ChEMBL_1569637 (CHEMBL3790863) Inhibition of doxorubicin-stimulated p53 (unknown origin) expressed in human RKO cells preincubated for 24 hrs followed by addition of doxorubicin for 16 hrs by luciferase reporter assay
- ChEMBL_2220674 (CHEMBL5134008) Inhibition of P-gp mediated doxorubicin resistance in human SW620/AD300 cells overexpressing P-gp in presence of doxorubicin measured after 52 hrs by MTT assay
- ChEMBL_1852724 (CHEMBL4353348) Inhibition of P-gp in human Caco2 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring reduction in doxorubicin IC50 at 2.2 uM incubated for 24 hrs by MTT assay
- ChEMBL_2160155 (CHEMBL5044905) Inhibition of P-glycoprotein overexpressed in human SW620/AD300 cells assessed as reversal of doxorubicin resistance by measuring doxorubicin IC50 at 2.5 uM after 48 hrs by MTT assay
- ChEMBL_2151090 (CHEMBL5035552) Inhibition of MRP1 in human 2008/MRP1 cells assessed as reversal of doxorubicin resistance by measuring doxorubicin IC50 at 1 uM after 5 days by Cell Titer-Glo luminescence assay
- ChEMBL_1442370 (CHEMBL3378328) Modulatory activity at P-gp assessed as doxorubicin IC50 in human K562 cells at 0.1 uM after 72 hrs by MTT assay (Rvb doxorubicin alone IC50 = 0.023 +/- 0.004 uM)
- ChEMBL_1442373 (CHEMBL3378894) Modulatory activity at P-gp assessed as doxorubicin IC50 in human K562 cells at 1 uM after 72 hrs by MTT assay (Rvb doxorubicin alone IC50 = 0.023 +/- 0.004 uM)
- ChEMBL_1442376 (CHEMBL3378897) Modulatory activity at P-gp assessed as doxorubicin IC50 in human K562 cells at 3 uM after 72 hrs by MTT assay (Rvb doxorubicin alone IC50 = 0.023 +/- 0.004 uM)
- ChEMBL_1500149 (CHEMBL3584583) Modulation of MRP1 (unknown origin) transfected in human 2008/MRP1 cells assessed as potentiation of doxorubicin-induced cytotoxicity measured as doxorubicin IC50 at 1 uM after 5 days by MTS assay
- ChEMBL_1852719 (CHEMBL4353343) Inhibition of P-gp in HEK293/ABCB1 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 1 uM incubated for 48 hrs by MTT assay (Rvb = 8.08 uM)
- ChEMBL_1442371 (CHEMBL3378329) Modulatory activity at P-gp assessed as doxorubicin IC50 in human K562/DOX cells at 0.1 uM after 72 hrs by MTT assay (Rvb doxorubicin alone IC50 = 2.00 +/- 0.24 uM)
- ChEMBL_1442374 (CHEMBL3378895) Modulatory activity at P-gp assessed as doxorubicin IC50 in human K562/DOX cells at 1 uM after 72 hrs by MTT assay (Rvb doxorubicin alone IC50 = 2.00 +/- 0.24 uM)
- ChEMBL_1442377 (CHEMBL3378898) Modulatory activity at P-gp assessed as doxorubicin IC50 in human K562/DOX cells at 3 uM after 72 hrs by MTT assay (Rvb doxorubicin alone IC50 = 2.00 +/- 0.24 uM)
- ChEMBL_1625308 (CHEMBL3867777) Inhibition of human ABCB1 transfected in HEK293 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 50 nM after 72 hrs by CCK8 assay (Rvb = 504.65 +/- 44.94 nM)
- ChEMBL_1625309 (CHEMBL3867778) Inhibition of human ABCB1 transfected in HEK293 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 100 nM after 72 hrs by CCK8 assay (Rvb = 504.65 +/- 44.94 nM)
- ChEMBL_1625310 (CHEMBL3867779) Inhibition of human ABCB1 transfected in HEK293 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 200 nM after 72 hrs by CCK8 assay (Rvb = 504.65 +/- 44.94 nM)
- ChEMBL_1625311 (CHEMBL3867780) Inhibition of human ABCB1 transfected in HEK293 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 500 nM after 72 hrs by CCK8 assay (Rvb = 504.65 +/- 44.94 nM)
- ChEMBL_1625312 (CHEMBL3867781) Inhibition of human ABCB1 transfected in HEK293 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 1000 nM after 72 hrs by CCK8 assay (Rvb = 504.65 +/- 44.94 nM)
- ChEMBL_1625333 (CHEMBL3867802) Inhibition of human ABCB1 expressed in KBV1 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 500 nM after 72 hrs by MTT assay (Rvb = 5.07 +/- 0.19 uM)
- ChEMBL_1625339 (CHEMBL3867808) Inhibition of human ABCB1 expressed in KBV1 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 50 nM after 72 hrs by MTT assay (Rvb = 5.07 +/- 0.19 uM)
- ChEMBL_1625340 (CHEMBL3867809) Inhibition of human ABCB1 expressed in KBV1 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 100 nM after 72 hrs by MTT assay (Rvb = 5.07 +/- 0.19 uM)
- ChEMBL_1625341 (CHEMBL3867810) Inhibition of human ABCB1 expressed in KBV1 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 200 nM after 72 hrs by MTT assay (Rvb = 5.07 +/- 0.19 uM)
- ChEMBL_1625342 (CHEMBL3867811) Inhibition of human ABCB1 expressed in KBV1 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 1000 nM after 72 hrs by MTT assay (Rvb = 5.07 +/- 0.19 uM)
- ChEMBL_1741908 (CHEMBL4157658) Inhibition of ABCB1 in human SW620/Ad300 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 10 uM after 72 hrs by MTT assay (Rvb = 6.15 +/- 0.63 microM)
- ChEMBL_1741909 (CHEMBL4157659) Inhibition of ABCB1 in human SW620/Ad300 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 20 uM after 72 hrs by MTT assay (Rvb = 6.15 +/- 0.63 microM)
- ChEMBL_1741910 (CHEMBL4157660) Inhibition of ABCB1 in human SW620/Ad300 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 4 uM after 72 hrs by MTT assay (Rvb = 6.15 +/- 0.63 microM)
- ChEMBL_1852723 (CHEMBL4353347) Inhibition of P-gp in human NCI-H460/R cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring reduction in doxorubicin IC50 at 0.1 to 2.5 uM incubated for 72 hrs by MTT assay
- ChEMBL_2089949 (CHEMBL4771212) Inhibition of ABCB1 in FLp-In-293 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 2.5 uM measured after 72 hrs by SRB assay (Rvb = 80 +/- 10 nM)
- ChEMBL_2089950 (CHEMBL4771213) Inhibition of ABCB1 in FLp-In-293 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 5 uM measured after 72 hrs by SRB assay (Rvb = 80 +/- 10 nM)
- ChEMBL_1741944 (CHEMBL4157694) Inhibition of ABCB1 (unknown origin) expressed in HEK293T cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 10 uM after 72 hrs by MTT assay (Rvb = 1.17 +/- 0.09 microM)
- ChEMBL_1741945 (CHEMBL4157695) Inhibition of ABCB1 (unknown origin) expressed in HEK293T cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 20 uM after 72 hrs by MTT assay (Rvb = 1.17 +/- 0.09 microM)
- ChEMBL_1741946 (CHEMBL4157696) Inhibition of ABCB1 (unknown origin) expressed in HEK293T cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 4 uM after 72 hrs by MTT assay (Rvb = 1.17 +/- 0.09 microM)
- ChEMBL_2089961 (CHEMBL4771224) Inhibition of ABCB1 in human HeLa S3 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 2.5 uM measured after 72 hrs by SRB assay (Rvb = 242 +/- 5 nM)
- ChEMBL_2089962 (CHEMBL4771225) Inhibition of ABCB1 in human HeLa S3 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 5 uM measured after 72 hrs by SRB assay (Rvb = 242 +/- 5 nM)
- ChEMBL_2089967 (CHEMBL4771230) Inhibition of ABCB1 in human KB-VIN cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 2.5 uM measured after 72 hrs by SRB assay (Rvb = 4736 +/- 59 nM)
- ChEMBL_2089968 (CHEMBL4771231) Inhibition of ABCB1 in human KB-VIN cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 5 uM measured after 72 hrs by SRB assay (Rvb = 4736 +/- 59 nM)
- ChEMBL_1625382 (CHEMBL3867851) Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 50 nM after 72 hrs by MTT assay (Rvb = 5.54 +/- 0.60 uM)
- ChEMBL_1625383 (CHEMBL3867852) Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 100 nM after 72 hrs by MTT assay (Rvb = 5.54 +/- 0.60 uM)
- ChEMBL_1625384 (CHEMBL3867853) Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 200 nM after 72 hrs by MTT assay (Rvb = 5.54 +/- 0.60 uM)
- ChEMBL_1625385 (CHEMBL3867854) Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 500 nM after 72 hrs by MTT assay (Rvb = 5.54 +/- 0.60 uM)
- ChEMBL_1625386 (CHEMBL3867855) Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 1000 nM after 72 hrs by MTT assay (Rvb = 5.54 +/- 0.60 uM)
- ChEMBL_1587216 (CHEMBL3825952) Inhibition of full length human ABCB1 expressed in Flp-In-293 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 8 uM after 72 hrs by SRB assay (Rvb = 914.83 +/- 15.85 nM)
- ChEMBL_1587217 (CHEMBL3825953) Inhibition of full length human ABCB1 expressed in Flp-In-293 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 10 uM after 72 hrs by SRB assay (Rvb = 914.83 +/- 15.85 nM)
- ChEMBL_1861058 (CHEMBL4361914) Reversal of P-gp-mediated multidrug resistance in human MCF7/Dox cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 12.5 uM after 48 hrs by MTT assay (Rvb = 51.19 +/- 0.95 microM)
- ChEMBL_1971684 (CHEMBL4604502) Reversal of P-gp mediated multidrug resistance in human SW620/AD300 cells assessed as potentiation of doxorubicin-induced antiproliferative activity by measuring doxorubicin IC50 at 2.5 uM after 48 hrs by MTT assay (Rvb = 4.9 microM)
- ChEMBL_2089955 (CHEMBL4771218) Inhibition of human full-length ABCB1 expressed in FLp-In-293 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 2.5 uM measured after 72 hrs by SRB assay (Rvb = 2264 +/- 196 nM)
- ChEMBL_2089956 (CHEMBL4771219) Inhibition of human full-length ABCB1 expressed in FLp-In-293 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 5 uM measured after 72 hrs by SRB assay (Rvb = 2264 +/- 196 nM)
- ChEBML_84786 In vitro for its inhibitory activity against MRP1-transfected HeLa-T5 cell line in the presence of doxorubicin
- ChEMBL_837645 (CHEMBL2076598) TP_TRANSPORTER: inhibition of Doxorubicin transepithelial transport (basal to apical) (Digoxin: 0.8 uM) in MDR1-expressing LLC-PK1 cells
- ChEMBL_882171 (CHEMBL2215003) Competitive inhibition of P-gp overexpressed in human MDA435/LCC6MDR cells assessed as accumulation of doxorubicin by Dixon plot analysis
- ChEMBL_882170 (CHEMBL2215002) Competitive inhibition of P-gp overexpressed in human MDA435/LCC6MDR cells assessed as accumulation of doxorubicin by Lineweaver-Burk plot analysis
- ChEMBL_934786 (CHEMBL2318920) Inhibition of P-glycoprotein in human doxorubicin-resistant K562 cells assessed as half maximal increase of pirarubicin accumulation by spectrofluorometric analysis
- ChEMBL_1822760 (CHEMBL4322524) Inhibition of MRP1 (unknown origin) expressed in human 2008/MRP1 assessed as reversal of doxorubicin resistance after 5 days by MTS/PMS assay
- ChEMBL_2119411 (CHEMBL4828477) Inhibition of MRP1 (unknown origin) expressed in human 2008/MRP1 cells assessed as reversal of doxorubicin resistance after 5 days by MTS/PMS assay
- ChEMBL_2220673 (CHEMBL5134007) Inhibition of P-gp mediated doxorubicin resistance in human SW620/AD300 cells overexpressing P-gp measured after 48 hrs by MTT assay
- ChEMBL_1788926 (CHEMBL4260660) Inhibition of MRP1 in human 2008/MRP1 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring reduction in cell survival after 5 days by MTS assay
- ChEMBL_1500059 (CHEMBL3584173) Modulation of P-gp (unknown origin) transfected in human MDA435/LCC6MDR cells assessed as reversing doxorubicin resistance measured as cell survival after 5 days by MTS assay
- ChEMBL_2108329 (CHEMBL4817004) Inhibition of P-glycoprotein in human MCF7/ADR cells assessed as reversal fold by measuring reduction in doxorubicin IC50 at 5 uM incubated for 48 hrs by CCK-8 assay
- ChEMBL_2073211 (CHEMBL4728745) Inhibition of human ABCC1-mediated multidrug resistance in MDCK2 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring half maximal reversal concentration after 72 hrs by MTT assay
- ChEMBL_1278744 (CHEMBL3096291) Inhibition of MDR1 in human doxorubicin-resistant A2780adr cells assessed as Calcein AM accumulation treated 30 mins before Calcein AM addition measured up to 90 mins by fluorescence assay
- ChEMBL_1561479 (CHEMBL3779616) Inhibition of p53-CBP bromodomain interaction in human U2OS cells assessed as inhibition of p21 activation incubated overnight followed by doxorubicin addition measured after 24 hrs by luciferase reporter gene assay
- ChEMBL_1814719 (CHEMBL4314293) Reversal of P-gp mediated multidrug resistance in human MCF7/ADM cells assessed as doxorubicin IC50 at 5 uM measured within 48 hrs by MTT assay (Rvb = 151.7 +/- 5 uM)
- ChEMBL_1814720 (CHEMBL4314294) Reversal of P-gp mediated multidrug resistance in human MCF7/ADM cells assessed as doxorubicin IC50 at 10 uM measured within 48 hrs by MTT assay (Rvb = 151.7 +/- 5 uM)
- ChEMBL_1814723 (CHEMBL4314297) Reversal of P-gp mediated multidrug resistance in human HepG2/DOX cells assessed as doxorubicin IC50 at 10 uM measured within 48 hrs by MTT assay (Rvb = 69.3 +/- 3.9 uM)
- ChEMBL_1814724 (CHEMBL4314298) Reversal of P-gp mediated multidrug resistance in human HepG2/DOX cells assessed as doxorubicin IC50 at 5 uM measured within 48 hrs by MTT assay (Rvb = 69.3 +/- 3.9 uM)
- ChEMBL_2073206 (CHEMBL4728740) Inhibition of human ABCB1-mediated multidrug resistance in human A2780/ADR cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring half maximal reversal concentration after 72 hrs by MTT assay
- ChEMBL_1437088 (CHEMBL3390819) Modulation of MRP1 mediated drug efflux in doxorubicin-resistant human H69 cells assessed as accumulation of calcein AM incubated for 15 mins prior to calcein AM addition measured after 30 mins by fluorescence analysis